<DOC>
	<DOCNO>NCT02256423</DOCNO>
	<brief_summary>This open-label , randomised , 3-period , 3-sequence single-dose crossover study determine comparative pharmacokinetic profile Test Investigational Medicinal Product ( IMP ) Ibuprofen 200 mg soft gel capsule ( lipid formulation ) reference product NurofenÂ® 200 mg tablet ibuprofen 200 mg soft gel capsule follow single dose administration healthy male female subject . The study comprise pre-study screen ( within 14 day first dose ) , follow 3 Treatment Periods ( 1 , 2 3 ) post study follow ( 3 - 7 day last dose ) . Each Treatment Period 1 day duration , afternoon dosing ( Day -1 ) 12 hour ( h ) post-dose ( Evening Day 1 ) . Study drug administer morning Day 1 follow overnight fast . PK sample collect pre-dose 12 h post-dose ( x15 sample ) measurement ibuprofen . Safety evaluate specify time throughout study . There least 48 h dose administration .</brief_summary>
	<brief_title>A Study Comparing Three Formulations Ibuprofen Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>1 . Healthy male females 18 50 year age . 2 . Female subject child bear potential negative pregnancy test Screening Visit willing use effective method contraception applicable ( unless nonchildbearing potential abstain sexual intercourse line prefer usual lifestyle subject ) Day 1 3 month afterwards . 3 . Female subject nonchild bearing potential negative pregnancy test Screening Visit . For purpose study , define subject amenorrheic least 12 consecutive month least 4 month postsurgical sterilisation ( include bilateral fallopian tube ligation bilateral oophorectomy without hysterectomy ) . Menopausal status confirm demonstrate screening level follicle stimulate hormone ( FSH ) fall within respective pathology reference range . In event subject 's menopause status clearly establish ( example , subject indicate amenorrheic 10 year ) , FSH level consistent postmenopausal condition , determination subject eligibility discretion Chief Investigator follow consultation Sponsor 's Responsible Physician . 4 . Subject Body Mass Index ( BMI ) 1830 kilogram ( kg ) /metre square ( m2 ) . Body Mass Index = Body weight kg / [ Height ] 2 . 5 . Subject clinically significant abnormal serum biochemistry , haematology urine examination value within 14 day first dose . 6 . Subject negative urinary drug abuse screen , determine within 14 day first dose ( positive alcohol result may repeat discretion Investigator ) . 7 . Subject negative human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( Hep B ) hepatitis C virus antibody ( Hep C ) result . 8 . Subject clinically significant abnormality 12lead ECG determine within 14 day first dose . 9 . Subject must available complete study ( include follow visit ) comply study restriction . 10 . Subject must satisfy medical examiner fitness participate study . 11 . Subject must provide write informed consent participate study . 1 . History allergy NSAIDs aspirin history peptic ulcer gastrointestinal bleeding . 2 . A clinically significant history gastrointestinal disorder likely influence drug absorption , Gastroesophageal reflux disease 3 . Receipt regular medication within 14 day first dose may impact safety objective study ( Investigator 's discretion ) . 4 . Evidence renal , hepatic , central nervous system , respiratory , cardiovascular metabolic dysfunction . 5 . A clinically significant history previous allergy / sensitivity ibuprofen . 6 . A clinically significant history drug alcohol abuse . 7 . Inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) . 8 . Participation New Chemical Entity clinical study within previous 4 month market drug clinical study within previous 3 month . ( N.B . washout period study define period time elapse last dose previous study first dose next study ) . 9 . Donation 450 mL blood within previous 3 month . 10 . Subjects current smoker , use nicotine product within previous 3 month . 11 . Subject positive human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( Hep B ) hepatitis C virus antibody ( Hep C ) result . 12 . Any subject , judgment Investigator , likely noncompliant study procedure and/or restriction study , unable cooperate language problem poor mental development . 13 . Subjects must take counter drug herbal remedy supplement take 7 day prior first dose throughout duration study dose period . 14 . Prescribed drug take 7 day first dose throughout duration study dose period . This include oral contraceptive pill .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Ibuprofen</keyword>
	<keyword>healthy volunteer study</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>